Vincerx Pharma, Inc. (VINC) Earnings History
Net Loss6 years of earnings data (2019–2024) · Currently unprofitable on a TTM basis
Loading earnings history...
Vincerx Pharma, Inc. (VINC) Earnings Overview
As of June 30, 2026, Vincerx Pharma, Inc. (VINC) reported trailing twelve-month net income of -$23M, reflecting +15.9% year-over-year growth. The company earned $-4.33 per diluted share over the past four quarters.
Looking at the long-term picture, VINC's historical earnings data spans multiple years. The company achieved its highest annual net income of -$54,000 in fiscal 2019.
Vincerx Pharma, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including AGIO (-$423M net income, -764.0% margin), KYMR (-$315M net income, -794.4% margin), PRAX (-$327M net income), VINC has comparable earnings metrics. Compare VINC vs AGIO →
VINC Earnings vs Peers
Earnings metrics vs comparable public companies
VINC Historical Earnings Data (2019–2024)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$30M | +25.1% | -$31M | $-5.75 | - | - |
| 2023 | -$40M | +38.6% | -$43M | $-6.84 | - | - |
| 2022 | -$65M | -66.3% | -$69M | $-10.86 | - | - |
| 2021 | -$39M | -136.5% | -$63M | $-8.30 | - | - |
| 2020 | -$17M | -30677.8% | -$11M | $-11.67 | - | - |
| 2019 | $-54,000 | - | $-45,000 | $-0.03 | - | - |
Download Data
Export VINC earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
VINC — Frequently Asked Questions
Quick answers to the most common questions about buying VINC stock.
What is VINC earnings per share (EPS)?
VINC trailing twelve-month (TTM) diluted EPS is $-4.33, reflecting +15.9% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2024 is available in the table on this page.
What is Vincerx Pharma, Inc.'s net income?
Vincerx Pharma, Inc. (VINC) trailing twelve-month net income is $-23M as of 2024. Earnings grew +15.9% year-over-year.
Is VINC profitable?
VINC is not currently profitable on a TTM basis, reporting a net loss of $-23M. Net margin is N/A. Investors should monitor for a return to profitability.
What is VINC's earnings growth rate?
VINC compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2024.
What are VINC's profit margins?
Vincerx Pharma, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -431.3%.
Is VINC growing earnings?
Yes, VINC earnings are accelerating — EPS growth of +15.9% exceeds the 5-year CAGR of N/A. TTM net income reached $-23M. Earnings momentum is strengthening.
What was VINC's best earnings year?
Vincerx Pharma, Inc.'s highest annual net income on record is $-54000.00, achieved in fiscal year 2019. Earnings history on this page spans 2019 to 2024 and includes all annual and quarterly figures.
What were VINC's earnings last quarter?
VINC's most recent reported quarter was Q1 2025. Net income was $-5M with diluted EPS of $-0.96. For a full breakdown of all quarters, see the quarterly earnings table on this page.